Up-regulation of Fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance

Hepatology

Volumn 32, Issue 4 I, 2000, Pages 761-769

  Shimonishi, Tomonori ^a,b   Isse, Kumiko ^a   Shibata, Fumie ^a   Aburatani, Isao ^a   Tsuneyama, Koichi ^a   Sabit, Hemragul ^a   Harada, Kenichi ^a   Miyazaki, Kohji ^b   Nakanuma, Yasuni ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

EID: 0033803793     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.18192     Document Type: Article

References (35)

1. Clinical and pathologic features of cholangiocarcinoma
2. Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply
3. Are hepatolithiasis and cholangiocarcinoma aetiologically related? A morphological study of 12 cases of hepatolithiasis associated with cholangiocarcinoma
4. Histological features and interphase nucleolar organizer regions in hyperplastic, dysplastic and neoplastic epithelium of intrahepatic bile ducts in hepatolithiasis
5. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
6. Apoptosis in the pathogenesis and treatment of disease
7. The Fas death factor
8. Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): A possible mechanism for lymphopenia
9. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood
10. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage
11. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity
12. A role for CD95 ligand in preventing graft rejection
13. Fas ligand-induced apoptosis as a mechanism of immune privilege
14. Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover
15. Fas expression and function in normal and malignant breast cell lines
16. Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back
17. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
18. Expression of Fas ligand by human gastric adenocarcinomas: A potential mechanism of immune escape in stomach cancer
19. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
20. Human lung carcinomas express Fas ligand
21. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
22. Fas ligand expression in primary colon adenocarcinomas: Evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer
23. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?
24. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
25. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?
26. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo?
27. Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion
28. Cholangiocarcinoma express Fas ligand and disable the Fas receptor
29. Constitutive expression of FasL in thyrocytes
30. Cytokeratin profile relates to histologic subtypes and intrahepatic location of intrahepatic cholangiocarcinoma and primary sites of metastatic adenocarcinoma of liver
31. The EnVision+ system: A new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques
32. Cutting edge: The tumor counterattack hypothesis revisited: Colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO1) pathway
33. Immune evasion by tumours: Involvement of the CD95 (APO-1/Fas) system and its clinical implications
34. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice